SCYNEXIS: Buy Rating Affirmed Amid Strategic Advancements and Promising Antifungal Innovations

Maxim Group analyst Jason McCarthy maintained a Buy rating on SCYNEXIS (SCYX – Research Report) yesterday and set a price target of $4.00.

Jason McCarthy has given his Buy rating due to a combination of factors including SCYNEXIS’s recent financial performance and strategic developments. The company reported its first quarter 2025 results, showing a modest revenue from its licensing agreement with GSK and maintaining a solid cash position expected to support operations into mid-2026. Additionally, the lifting of the FDA clinical hold on the Phase 3 MARIO study for Brexafemme marks a significant advancement, allowing the company to resume the study despite ongoing negotiations with GSK regarding the agreement termination.
Furthermore, SCYNEXIS is progressing with its next-generation oral antifungal asset, SCY-247, which is currently undergoing a Phase 1 safety and pharmacokinetics study with results anticipated in the third quarter of 2025. The company’s focus on innovative antifungal treatments, such as the first-in-class triterpenoid antifungal ibrexafungerp, which has shown promising results in various studies, supports its potential for future growth. These developments collectively underpin McCarthy’s optimistic outlook and Buy rating for SCYNEXIS.

McCarthy covers the Healthcare sector, focusing on stocks such as Actinium Pharmaceuticals, Gain Therapeutics, and SELLAS Life Sciences Group. According to TipRanks, McCarthy has an average return of -21.7% and a 26.41% success rate on recommended stocks.